Evidence map›Paper›PMID 40080912›Full record

ArticleMolecular oncology2025

Revisiting CDKN2A dysregulation in Ewing sarcoma.

Anjali Paragji, Vivek Shastri, Elham Nasri, John A Ligon, Leighton A Elliott, Paul Castillo-Caro, Jatinder K Lamba, Elias J Sayour, Nathan D Seligson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anjali ParagjiDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, The University of Florida, Jacksonville, FL, USA.
Vivek ShastriDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, The University of Florida, Jacksonville, FL, USA.
Elham NasriDepartment of Pathology, College of Medicine, The University of Florida, Gainesville, FL, USA.
John A LigonDepartment of Pediatrics, College of Medicine, The University of Florida, Gainesville, FL, USA.
Leighton A ElliottDepartment of Pediatrics, College of Medicine, The University of Florida, Gainesville, FL, USA.
Paul Castillo-CaroDepartment of Pediatrics, College of Medicine, The University of Florida, Gainesville, FL, USA.
Jatinder K LambaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, The University of Florida, Jacksonville, FL, USA.
Elias J SayourDepartment of Neurosurgery, College of Medicine, The University of Florida, Gainesville, FL, USA.
Nathan D SeligsonDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, The University of Florida, Jacksonville, FL, USA.ORCID https://orcid.org/0000-0002-9670-3792

Funding

University of Florida
6 · The paper itself

Abstract

Ewing sarcoma (EwS) is a rare and aggressive malignancy, which frequently affects children. One of the few recurrent genomic variants in EwS is genomic copy number deletion of CDKN2A; however, the clinical consequences of dysregulation of CDKN2A in EwS are unclear. In this study, we revisit CDKN2A to investigate its role as a potential prognostic biomarker in EwS using data from EwS pre-clinical models as well as clinical samples from patients with EwS. We demonstrate the potential essentiality of CDKN2A dysregulation and sustained downstream CDK4/CCND1 activity. Finally, we present evidence that high expression of CDKN2A is a negative prognostic biomarker at diagnosis in EwS in three independent datasets. Our data may suggest that the role of CDKN2A may change across the clinical context of EwS, however, further study is necessary to validate the function of CDKN2A expression in EwS.

Indexed as

Bone NeoplasmsCyclin-Dependent Kinase Inhibitor p16Gene Expression Regulation, NeoplasticSarcoma, EwingBiomarkers, TumorCell Line, TumorChildCyclin D1Cyclin-Dependent Kinase 4FemaleHumansMalePrognosisBiomarkers, TumorCDKN2A protein, humanCyclin D1Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase Inhibitor p16biomarkernext‐generation sequencingprognosis

Identifiers

PMID40080912
PMCPMC11977643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.